Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Pekarik

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
International Journal of Nanomedicine|May 6, 2024
Nanoformulation of the Broad-Spectrum Hydrophobic Antiviral Vacuolar ATPase Inhibitor Diphyllin in Human Recombinant <i>H</i>-ferritinMichaela Vojnikova, Martina Sukupova, Michal Stefanik, et al.
Pharmacological Research|December 7, 2020
Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed ratsMartina Di Bartolomeo, Tibor Stark, Oriana Maria Maurel, et al.
Neuropharmacology|November 30, 2018
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophreniaTibor Stark, Jana Ruda-Kucerova, Fabio Arturo Iannotti, et al.
Biochemical Pharmacology|May 4, 2020
Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatmentTibor Stark, Martina Di Bartolomeo, Roberta Di Marco, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
International Journal of Nanomedicine|May 6, 2024
Nanoformulation of the Broad-Spectrum Hydrophobic Antiviral Vacuolar ATPase Inhibitor Diphyllin in Human Recombinant <i>H</i>-ferritinMichaela Vojnikova, Martina Sukupova, Michal Stefanik, et al.
Pharmacological Research|December 7, 2020
Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed ratsMartina Di Bartolomeo, Tibor Stark, Oriana Maria Maurel, et al.
Neuropharmacology|November 30, 2018
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophreniaTibor Stark, Jana Ruda-Kucerova, Fabio Arturo Iannotti, et al.
Biochemical Pharmacology|May 4, 2020
Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatmentTibor Stark, Martina Di Bartolomeo, Roberta Di Marco, et al.
Pageof 3